Introduction
Lung cancer is the second most common cancer regarding new cases (15% of all cancers in the US) (Jemal et al., 2007) and is the leading cause of cancer deaths worldwide (31% in men and 26% women in the US). Four out of five lung carcinomas are non-small cell lung cancers (NSCLC) and about one third of NSCLC patients are diagnosed with an early disease. Surgery is the best treatment option for these patients, yet a high percentage of patients relapse and the majority die of their disease. Patients within identical cancer stages often show differing recurrence rates (Zhu et al., 2006) ; therefore there is an interest in molecular markers, which could identify patients more likely to recur after surgery (D'Amico, 2008) . Several potential markers for metastatic recurrence of NSCLC have been tested, but none of them has proven sufficiently useful (Zhu et al., 2006) .
In our study, we show that expression of the human histone variant macroH2A can predict lung cancer recurrence and could therefore serve as a useful prognostic biomarker. We find that the prognostic correlation of macroH2A1.1 expression is superior to the proliferation marker Ki-67, which is commonly used to estimate cancer patient prognosis. We observe a strong negative correlation between the macroH2A1.1 and macroH2A2 expression and tumor proliferation rate. Slowly proliferating tumors tend to show high expression of macroH2A1.1 and macroH2A2, whereas tumors with a high proliferative index, which are often clinically more aggressive, have lower or no expression.
MacroH2A has been implicated in a permanent growth-arrest known as senescence (Pehrson and Fried, 1992; Zhang et al., 2005) . This phenomenon has been described for primary cell cultures in vitro (Hayflick, 1965) and is a response to stresses like telomere shortening, accumulation of DNA damage and the overexpression of certain oncogenes (Serrano et al., 1997) . It is interesting to note that oncogene-induced senescence has emerged as a potent antitumor mechanism in vivo (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005; Collado and Serrano, 2006) . Here, we also show that macroH2A1.1 is upregulated in senescent cells, consistent with the finding that macroH2A1.1 is more highly expressed in tumors with better prognosis.
Results
Proliferation and macroH2A1.1 histone abundance correlate inversely There are three gene products for the two human macroH2A genes, all containing an N-terminal H2A-like fold and a C-terminal macro domain. MacroH2A1.1 and macroH2A1.2 are produced through alternative splicing of the H2AFY gene product, whereas macro-H2A2 is encoded by a second gene, H2AFY2. In vitro, the macro domain of macroH2A1.1, but not the other isoforms, binds ADP-ribose and related NAD metabolites (Kustatscher et al., 2005) . We generated specific antibodies to detect and distinguish the different macroH2A isoforms (Supplementary Figure 1) .
It has been suggested that macroH2A1.1 expression may be restricted to differentiated, non-proliferative tissues (Pehrson et al., 1997) . To analyze any correlations between macroH2A1.1 protein expression and cell proliferation, we performed immunohistochemical stainings on tissue microarrays (TMAs) containing breast cancer samples of 260 patients (Figure 1) . We assessed the expression levels of macroH2A and the proliferation marker Ki-67 in all tumor cells within a core. Histone H3 staining served as a positive control and showed strong nuclear staining in every cell within the cores (Supplementary Figure 2) . We assessed the relationship between Ki-67 and macroH2A1.1 expression using a conditional linear association test stratified by array. We find that macroH2A1.1 expression is highly correlated to Ki-67 levels (Po0.001), showing a decrease in macroH2A1.1 with the increase of Ki-67 positive cancer cells. A similar relationship is observed for mH2A2 (Po0.001), whereas macroH2A1.2 is expressed ubiquitously in these tumors (Figure 1) . The latter could be in part due to a higher affinity of the antibody against macroH2A1.2, which might make it difficult to compare subtle changes in the expression levels. However, there clearly are tissues in which we can see and discriminate highly varying expression levels for macroH2A1.2 (such as skeletal muscle, data not shown). These assays establish that the expression of the splice variant macroH2A1.1 is limited to tumors showing lower proliferation indices.
MacroH2A1.1 as a marker for cells that exited the cell cycle To test how cell proliferation and macroH2A1.1 levels correlate in a set of human tumors with complete clinical parameters, we scored samples from 39 NSCLC patients, which were found resectable and underwent surgery (22 adenocarcinomas and 17 squamous cell carcinomas; Supplementary Table 1) . Within 1 year after surgery, tumors recurred in 18 patients, whereas 21 patients remained recurrence-free. Similar to what we observe in breast cancer arrays, statistical analysis of the lung tumor array reveals that macroH2A1.1 expression is strongly correlated with Ki-67 levels (Po0.001) and decreases with the increase of Ki-67 positive cancer cells (Figure 2a To further test this notion, we analyzed immunohistochemical sections from a mouse model of tumor senescence induced by K-RasG12V (Guerra et al., 2003) . Our stainings reveal higher macroH2A1.1 expression in premalignant adenoma lesions, in which hallmark is an abundance of senescent cells (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005) , in comparison to the corresponding malignant adenocarcinomas (Figure 3a) . In contrast, the splice variant macroH2A1.2 is expressed at similar levels in adenomas and adenocarcinomas. This expression pattern defines macroH2A1.1 as an oncogene-induced senescence marker. Our observations are compatible with the idea of increased macroH2A1.1 expression in post-mitotic cells, including cellular senescence (Collado et al., 2005) .
MacroH2A1.1 expression predicts the risk of lung cancer recurrence To identify whether there is a dependence of disease-free survival (recurrence) with macroH2A1.1 expression, we carried out a conditional log-rank test, stratified by array (Hothorn et al., 2006) . Interestingly, it reveals a significant correlation between macroH2A1.1 expression and disease-free survival (P ¼ 0.0058). Patients with low macroH2A1.1 levels in lung tumor samples recur more likely than those with strong nuclear macroH2A1.1 staining (Figure 2c) . A similar, but weaker, correlation is also observed for the expression of macroH2A2 (P ¼ 0.04146; Supplementary Figure 3) . In contrast, macroH2A1.2, which is ubiquitously expressed (Supplementary Figure 4 ), shows no prognostic correlation to tumor recurrence. It is noted that the expression of the common proliferation marker Ki-67 does not show a significant correlation with disease-free survival (P ¼ 0.07983). Thus, our immunostaining and clinical data identify histone macroH2A1.1 as a novel, superior and potentially useful biomarker of lung cancer recurrence.
MacroH2A histones are upregulated in senescence
To further characterize the heterochromatic histone macroH2A during senescence, we performed immunofluorescent stainings of primary fibroblasts and observe that macroH2A1 isoforms are upregulated during replicative senescence. MacroH2A1.1 is expressed at higher levels in pre-senescent and senescent cells, as well as localizing to senescence-associated heterochromatic foci (SAHF) (Narita et al., 2003) in senescent cells (Figure 3b) . Similarly, macroH2A1.2 is also upregulated, in contrast to control proteins, such as the canonical histone H2A. Further, the enrichment of macroH2A in SAHF is not a mere consequence of the condensed nature of SAHF chromatin, as cellular macroH2A enrichment and SAHF incorporation follow slower kinetics than the formation of DAPI-enriched heterochromatic structures (unpublished observations), confirming earlier reports (Zhang et al., 2005) . This finding is supported by Western blots on human normal diploid fibroblasts IMR90, expressing hTERT and MEK:ER (ITM cells; Collado et al., 2005) . This system allows for switchable activation of MEK kinase, a downstream effector of Ras-induced senescence. The results show upregulation of macroH2A1.1 and macro-H2A1.1 histone protein in senescent cells (Figure 3c ). In contrast, canonical histone H2A seems to be mildly downregulated on the induction of senescence.
Discussion
Histones are often assumed to be present at similar levels in distinct cell types. The heterochromatic histone variant macroH2A is unusual in several molecular and cellular features. At the structural level, it bears a large C-terminal extension, the macro domain, a globular module of B25 kDa, which in the case of macroH2A1.1 binds ADP-ribose with high specificity (Kustatscher et al., 2005) . Further, there are two genes for macro-H2A, conserved in all vertebrates, and a second splice variant for macroH2A1, known as macroH2A1.2, which cannot bind small molecules. Here, we have developed polyclonal and monoclonal antibodies against all macroH2A isoforms (macroH2A1.1, macroH2A1.2 and macroH2A2) and used these antibodies to study the cellular localization and abundance of macroH2A histones in cultured cells and in vivo. We have found that macroH2A is upregulated in primary fibroblasts that have undergone replicative senescence. In addition, there is a strong negative correlation between the expression of macroH2A1.1 and Ki-67 in human cancer. Tumors undergoing rapid cell division (marked by high expression of the proliferation marker Ki-67) express low levels of macroH2A1.1, whereas tumors with low mitotic index are enriched for the histone. Both findings argue that macroH2A1.1 is correlated to the degree of differentiation of cells and marks cells that have exited the cell cycle.
The finding that macroH2A1.1 is enriched in rodent lung adenomas known to have a high number of senescent cells, but is downregulated or absent in lung carcinomas that have overcome senescence and display uncontrolled proliferation, is also consistent with these conclusions, underlining the idea of senescence as an antitumor mechanism. Significantly, we find that macro-H2A1.1 levels are a good predictor for the risk of tumor recurrence in lung cancer. In the defined number of patients we could analyze, it proved to be statistically superior to the correlation with the common proliferation marker, Ki-67 (P ¼ 0.0058 for macroH2A1.1 and P ¼ 0.07983 for Ki-67).
Currently available patient information for the breast cancer tissue array is insufficient to assess correlations and senescent (enlarged nuclei) WI38 primary fibroblasts. MacroH2A1.1 and macroH2A1.2 localize to senescence-associated heterochromatic foci (SAHF) and are expressed at higher levels in senescent cells. In contrast, canonical histone H2A is not changed by senescence. (c) Western blot of macroH2A1 upregulation during senescence. ITM cells are primary fibroblasts engineered to undergo simultaneous oncogene-induced senescence on addition of the tamoxifen analog 4OHT (Collado et al., 2005) . We consistently observe elevated levels of macroH2A1 in senescent cells. Protein levels of canonical histones H2A and H3 are slightly reduced in senescent cells. between macroH2A1.1 levels and clinical outcome. On the basis of our data from lung tumors, it is likely that macroH2A1.1 could be a useful prognostic biomarker also in breast cancer. Further testing will reveal its usefulness in different cancers.
The mechanisms underpinning macroH2A1.1 gene product upregulation during cellular senescence and its role in carcinogenesis remain to be elucidated. Preliminary evidence suggests that macroH2A1 mRNA levels do not alter during senescence (JCS and AGL; data not shown), suggesting that post-transcriptional processes may account for the upregulation of macroH2A1.1.
Our statistically supported observation of macro-H2A1.1 expression with disease-free survival opens the prospect of an improved stratification of recurrence risk in lung cancer patients and should be repeated with a bigger patient population. Future studies will provide important insight into whether macroH2A1.1 upregulation is a general feature of senescent cells in human tumors and whether high macroH2A1.1 staining generally reflects the degree of cellular differentiation in tumor cells. Our new tool promises to improve the identification of high-risk lung cancer patients, thus allowing for better targeting of therapeutic strategies in cancers with difficult prognosis.
Materials and methods
Generation of antibodies MacroH2A1.1 (amino acids 198-226) and macroH2A1.2 (198-228) were purified as GST-fusion proteins. The macro domain of macroH2A2 (162-372) was purified as a (His) 6 -tag fusion. Antibodies were recovered from rabbit serum (Eurogentec, Seraing, Belgium) using Hi-Trap Protein-G HP columns (GE Healthcare, Munich, Germany). Recombinant, (His) 6 -tagged macro domains for the macroH2A isoforms were coupled to Hi-Trap NHS-activated HP (GE Healthcare) and used for affinity purification of isoform-specific antibodies.
Breast cancer tissue microarrays
Breast cancer TMAs were provided by the National Center of Tumor Diseases (NCT), Heidelberg, Germany. They contained formalin-fixed and paraffin-embedded samples of 260 patients, with two samples per patient on each slide, distributed to different blocks. All breast cancer patients were female, median age of 58 years (range: 30-88 years). Clinical data associated with these patients were insufficient for further analysis.
Lung cancer patients and lung tissue microarrays Lung cancer TMAs were provided by the Thoraxklinik Heidelberg, Germany, and the NCT (TM, PS and Dr Esther Herpel). The slides contained samples of 41 patients with NSCLC that were found to be resectable and underwent surgery between March and December 2004 (23 with adenocarcinoma and 18 with squamous cell carcinoma). Samples of these patients collected during surgery were formalin-fixed and paraffinembedded and used to construct a TMA, which also included control samples. For quality reasons samples of two patients could not be analyzed, such that 39 patient samples were included in the analysis. See Supplementary Table 1 for the clinical characteristics of the study population. The collection and use of the human materials was approved by the local ethics committee (ethical vote # 270/2001, updated 2005) . Patients provided informed consent.
Immunohistochemistry
Immunohistochemical staining for macroH2A1.1, macro-H2A1.2, macroH2A2, Ki-67 (Dako, Glostrup, Denmark monoclonal mouse anti-human Ki-67, clone MIB-1, 1:100) and histone H3 (Abcam, Cambridge, UK; ab1791; 1:1000 dilution) was performed using successive TMA slides. Slides were scanned at the Department of Pathology (Heidelberg University) using the Aperio ScanScope System and ImageScope software.
Expression levels of macroH2A were assessed semi-quantitatively using the scoring: 0-1, negative/weak staining; 1-2, moderate staining; 2-3, strong nuclear positivity. Proliferation indexes were determined with antibodies against the proliferation marker Ki-67 and scored as the percentage of positively stained tumors cells in comparison with all the tumor cells within a core. All slides were evaluated and scored blindly, and repeated twice.
For the analysis of the macroH2A isoforms in mouse tumors, lungs from activated 7-9 months old K-Ras þ /G12Vgeo mice (Guerra et al., 2003) were dissected, fixed in 10%-buffered formalin (Sigma, St Louis, MO, USA) and embedded in paraffin. Consecutive 3-to 5-mm-thick sections were stained with hematoxylin and eosin, and processed for immunohistochemical staining using macroH2A1.1 and macroH2A1.2 antibodies (1:75 dilution). Grading of lung lesions was done according to the latest morphological accepted criteria for mouse lung cancer (Jackson et al., 2005) by an expert pathologist. Grade 1-3 neoplasms were classified as adenomas (benign lesions) and grade 4-5 as adenocarcinomas (malignant lesions).
Statistical analysis
The relationship between Ki-67 and mH2A1.1 was assessed using a conditional linear association test stratified by array (Hothorn et al., 2006) . The dependence of disease-free survival on mH2A1.1 was established by a conditional log-rank test, also stratified by array (Hothorn et al., 2006) .
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